10.1055/a-2461-3147 We read with great interest the systematic review and meta-analysis by Galvao et al.[1] evaluating the clinical efficacy of histidine–tryptophan–ketoglutarate (HTK) solution compared with other cardioplegic strategies in pediatric cardiac surgery. The authors should be commended for addressing an important and relatively underexplored topic in pediatric cardiac surgery, where evidence remains limited and practice variation persists. Their effort to synthesize available data on mortality, perioperative outcomes, and postoperative complications provides a valuable contribution to the literature and helps draw attention to the ongoing need for evidence-based myocardial protection strategies in this vulnerable population. However, despite the relevance and merit of this work, the study has the following limitations. First, the author's conclusion appears stronger than the underlying evidence permits. Although HTK was described as having “similar efficacy” to other cardioplegic strategies, the review was largely based on nonrandomized studies, with only three randomized trials, and several key pooled outcomes showed substantial to considerable heterogeneity. Moreover, the authors themselves rated outcomes such as low cardiac output syndrome and transfusion as low-quality evidence, whereas ICU stay and mechanical ventilation demonstrated marked inconsistency. In this context, concluding comparable efficacy may overstate the certainty of the findings; a more appropriate interpretation would be that current evidence remains insufficient to establish equivalence or superiority with confidence. Future reviews should align their conclusions more explicitly with the certainty of evidence, avoid definitive statements of comparable efficacy when the evidence is predominantly observational or inconsistent, and prioritize adequately powered multicenter randomized trials with standardized outcome definitions to provide more reliable comparative estimates.[2] Second, a major methodological concern is the pooling of markedly dissimilar control strategies into a single comparator group. In this review, the control arm included St. Thomas solution, Del Nido, warm blood, cold blood, intermittent blood, and other blood-based cardioplegia approaches, which differ in composition, delivery pattern, and clinical application. Such variation represents important clinical heterogeneity and can make a single pooled estimate difficult to interpret. Current methodological guidance recommends exploring heterogeneity through prespecified subgroup analysis or related approaches when meaningful differences across comparisons are expected. In this context, comparator-specific subgroup analyses would have been particularly relevant, as the effect of HTK may not be uniform against all alternative cardioplegic solutions. By not separating these control groups, the review may have obscured clinically important differences and weakened the certainty of its overall conclusion. Future systematic reviews should prespecify comparator-based subgroup analyses, and where data permit, consider meta-regression or network meta-analysis to better distinguish the relative effects of HTK against specific alternative cardioplegic solutions.[3] In summary, we appreciate the authors' contribution to an important and underexplored area of pediatric cardiac surgery. However, the methodological limitations of the review, particularly the predominance of nonrandomized evidence, heterogeneity across pooled outcomes, and broad comparator grouping, warrant a more cautious interpretation of the findings. Clarifying these issues in future studies will help strengthen the evidence base for cardioplegic strategies in children. Received: 08 April 2026 Accepted: 17 April 2026 Article published online: 30 April 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany